Clinical Trials Logo

2019 nCoV, PD-1 clinical trials

View clinical trials related to 2019 nCoV, PD-1.

Filter by:
  • None
  • Page 1

NCT ID: NCT04268537 Not yet recruiting - 2019 nCoV, PD-1 Clinical Trials

Immunoregulatory Therapy for 2019-nCoV

Start date: February 10, 2020
Phase: Phase 2
Study type: Interventional

Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died. Studies in China also showed that more than 1 million patients died of sepsis in 2015. Previous studies have suggested that sepsis are often secondary to excessive inflammatory response syndrome. However, treatment measures targeting excessive inflammatory response failed to effectively improve the prognosis of patients. PD-1 and PD-L1 are key mediators in T cell depletion in sepsis patients. Therefore, the investigators try to performe a clinical research to investigate the efficacy of PD-1 and thymosin in patients with severe pneumonia associated with lymphocytopenia in 2019 novel coronavirus infection.